Please join our President and CEO, Norbert Bischofberger, Ph.D, as he shares company highlights today at H.C. Wainwright & Co., LLC's 26th Annual Global Investment Conference at 2:30PM EST. You can listen to the audio webcast here: www.kronosbio.com
Kronos Bio
Biotechnology Research
San Mateo, California 9,330 followers
We’re focused on creating a world where no life is cut short by cancer or other serious diseases.
About us
Kronos Bio is a clinical-stage biopharmaceutical company developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. At Kronos Bio, we have two molecules that have emerged from our product engine. KB-0742, our CDK9 inhibitor, is being evaluated in a phase 1/2 clinical trial as a treatment for patients with MYC-dependent tumors such as triple negative breast cancer, non-small cell lung cancer and ovarian cancer, as well as patients with transcription factor fusion-driven cancers and other transcriptionally addicted cancers including chordomas, sarcomas and small cell lung cancer. Our new development candidate, KB-9558, targets the KAT domain of p300, a critical node of the IRF4 TRN, which is a core oncogenic transcription program that drives multiple myeloma. Additionally, Kronos Bio began a discovery collaboration with Genentech in January 2023. Our companies are working together to advance novel therapies against transcriptional targets in oncology. For additional information about our community guidelines, visit: https://bit.ly/3FfcDQW.
- Website
-
http://www.kronosbio.com
External link for Kronos Bio
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Mateo, California
- Type
- Public Company
- Founded
- 2017
Locations
-
Primary
1300 S El Camino Real
Suite 400
San Mateo, California 94402, US
-
301 Binney St.
2nd Floor East
Cambridge, Massachusetts 02142, US
Employees at Kronos Bio
Updates
-
Join us this month as we present at the H.C. Wainwright & Co., LLC 26th Annual Global Investment Conference, and data at the American Association for Cancer Research Biennial Ovarian Cancer Research Symposium and International Myeloma Society 21st Annual Meeting. Learn more here: https://bit.ly/47dBwe3 #ovariancancer #CDK9Inhibitor #multiplemyeloma
-
Today, we reported our second quarter 2024 financial results, recent corporate highlights and provided updates on our programs. We're excited by the progress of our programs both in the clinic and expanding our pipeline targeting deregulated transcription and look forward to multiple updates in 2025. Learn more at https://bit.ly/4ceRy85.
-
-
Kronos Bio reposted this
Today, Kronos Bio announced that the first patient was dosed at an 80mg four-days-on, three-days-off dose schedule with KB-0742, an oral CDK9 inhibitor, in an expansion cohort focused on enrolling patients with platinum-resistant high-grade serous ovarian cancer (HGSOC). Link to press release: https://bit.ly/46dVRPT #oncology #ovariancancer #biotech
-
Today, Kronos Bio announced that the first patient was dosed at an 80mg four-days-on, three-days-off dose schedule with KB-0742, an oral CDK9 inhibitor, in an expansion cohort focused on enrolling patients with platinum-resistant high-grade serous ovarian cancer (HGSOC). Link to press release: https://bit.ly/46dVRPT #oncology #ovariancancer #biotech
-
As we approach the end of Pride month, we wanted to highlight how we celebrated with our teams in San Mateo, CA by holding a social gathering with delicious doughnuts decorated in Pride colors and in Cambridge, MA by holding a cookie decorating activity. During Pride month and all year long, we celebrate our LGBTQ+ employees as well as the broader community. #PrideMonth #Pride2024
-
Today, Kronos Bio honors #Juneteenth and recognizes the importance of this day and the work that still needs to be done to achieve equality for all. We remain committed to fostering a diverse and inclusive environment where everyone can thrive.
-
-
Today at the Jefferies Global Healthcare Conference in New York, our president and chief executive officer, Dr. Norbert Bischofberger, Ph.D., will present a corporate overview at 1:30 p.m. ET/10:30 a.m. PT. Listen live to the presentation or the replay at the webcast link: https://bit.ly/3Va9JVX #biotech #investors #JefferiesHealthcare
-
-
Today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Brian A. Van Tine, M.D., Ph.D., presented updated study data from KB-0742-1001, from our CDK9 inhibitor KB-0742, in a poster session. Our team was thrilled to see the interest in the data during the session. Poster Board #247 Link to Poster: https://bit.ly/45dGxSQ #ASCO2024 #oncology #biotech
-